Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetics of cyclophosphamide in man.

Literature DB >> 5157730

Pharmacokinetics of cyclophosphamide in man.

Abstract

1. The pharmacokinetics of cyclophosphamide were investigated in cancer patients. The data can be characterized by a two-compartment open model. The half life of the elimination phase of the drug ranged between 3 and 11 hours.2. Extensive tubular reabsorption of the drug resulted in the excretion of only a small percentage of the administered dose. The mean renal clearance was 10.7 ml/minute.3. The calculated fraction of the dose of drug which was metabolized averaged 88%.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1971 PMID： 5157730 PMCID： PMC1665783 DOI： 10.1111/j.1476-5381.1971.tb07199.x

Source DB: PubMed Journal: Br J Pharmacol ISSN： 0007-1188 Impact factor: 8.739

7 in total

1. [ON THE ACTIVATION OF CYCLOPHOSPHAMIDE IN VIVO AND IN VITRO].

Authors: N BROCK; H J HOHORST
Journal: Arzneimittelforschung Date: 1963-12

2. Studies on the mechanism of action of cytoxan. Evidence of activation in vivo and in vitro.

Authors: G E FOLEY; O M FRIEDMAN; B P DROLET
Journal: Cancer Res Date: 1961-01 Impact factor: 12.701

3. Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat.

Authors: J L Cohen; J Y Jao
Journal: J Pharmacol Exp Ther Date: 1970-08 Impact factor: 4.030

4. Effect of mode of administration on drug distribution in a two-compartment open system.

Authors: M Gibaldi
Journal: J Pharm Sci Date: 1969-03 Impact factor: 3.534

5. Pharmacokinetic evidence for saturable renal tubular reabsorption of riboflavin.

Authors: W J Jusko; G Levy
Journal: J Pharm Sci Date: 1970-06 Impact factor: 3.534

6. Metabolism of radioactive cyclophosphamide. Animal tests and clinical studies.

Authors: E H Graul; E Schaumlöffel; H Hundeshagen; H Wilmanns; G Simon
Journal: Cancer Date: 1967-05 Impact factor: 6.860

7. Immunosuppressive therapy in steroid-resistant proliferative glomerulonephritis accompanied by the nephrotic syndrome.

Authors: R H White; J S Cameron; J R Trounce
Journal: Br Med J Date: 1966-10-08

7 in total

21 in total

Review 1. Clinical pharmacokinetics of cyclophosphamide.

Authors: L B Grochow; M Colvin
Journal: Clin Pharmacokinet Date: 1979 Sep-Oct Impact factor: 6.447

2. Pharmacokinetics of cyclophosphamide in Kenyan Africans.

Authors: F Juma; T Ogada
Journal: Br J Clin Pharmacol Date: 1983-07 Impact factor: 4.335

3. The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy.

Authors: F D Juma; H J Rogers; J R Trounce
Journal: Br J Clin Pharmacol Date: 1980-10 Impact factor: 4.335

Pharmacokinetics of cyclophosphamide in man.

1. [ON THE ACTIVATION OF CYCLOPHOSPHAMIDE IN VIVO AND IN VITRO].

2. Studies on the mechanism of action of cytoxan. Evidence of activation in vivo and in vitro.

3. Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat.

4. Effect of mode of administration on drug distribution in a two-compartment open system.

5. Pharmacokinetic evidence for saturable renal tubular reabsorption of riboflavin.

6. Metabolism of radioactive cyclophosphamide. Animal tests and clinical studies.

7. Immunosuppressive therapy in steroid-resistant proliferative glomerulonephritis accompanied by the nephrotic syndrome.

Review 1. Clinical pharmacokinetics of cyclophosphamide.

2. Pharmacokinetics of cyclophosphamide in Kenyan Africans.

3. The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy.

4. Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.

5. Comparative effects of ASTA Z 7557 (INN mafosfamide) and cyclophosphamide on hematopoiesis in mice.

6. Preclinical pharmacokinetics and stability of isophosphoramide mustard.

7. The disposition of cyclophosphamide in a group of myeloma patients.

Review 8. Pharmacokinetics of anticancer drugs in children.

9. Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.

10. Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography.